Shares of HCW Biologics (HCWB) ticked up 3.5% to $2.05 after the company disclosed that a Nasdaq Hearings Panel granted it additional time to regain compliance with the exchange's $1.00 minimum bid-price rule — a threshold that, if permanently breached, results in delisting. The reprieve removes the most immediate existential risk, but the company's deeper challenges remain unsolved. HCW Biologics Escapes Nasdaq's Chopping Block Again, but Can a Company With $1.2 Million in Cash Outrun the Clock?

Shares ticked up 3.5% to $2.05 after HCW Biologics disclosed that a Nasdaq Hearings Panel granted it more time to satisfy the exchange's $1.00 minimum bid-price rule — the threshold below which a stock gets kicked off the exchange. The relief removes the most immediate threat of delisting, but for a company that has already executed a 1-for-40 reverse stock split just 14 months ago for the same reason, the reprieve looks more like a bandage than a cure.

• A Familiar Pattern: This Is HCWB's Second Compliance Crisis in Under a Year

Because the company already executed a 1-for-40 reverse stock split in April 2025, it was not afforded the standard 180-day grace period to regain compliance.

The Panel granted the extension on May 29 following a hearing on May 5, where management presented its plan to get the stock back above $1.00. Investors should understand this is a recurring fight: the company remains under a one-year Mandatory Panel Monitor from January 2026, meaning any new violation triggers accelerated consequences rather than another second chance.

• A Profitable Quarter That May Not Repeat

Q1 2026 showed a dramatic swing to profitability — $6.54 million in revenue and diluted EPS of $0.37 — compared with virtually no revenue a year earlier. But the entire top line came from a single event: a one-time exclusive worldwide license deal with Beijing Trimmune, which brought $3.5 million in cash and a $3.5 million equity stake. Licensing deals are lumpy; without a follow-on transaction, revenue could collapse next quarter.

• The Cash Runway Is Razor-Thin

As of March 31, the company held just $1.23 million in cash.

Management itself warns "substantial doubt exists about its ability to continue as a going concern" without additional funding.

A $5.6 million equity offering was filed in April but terminated in May, underscoring how difficult it is to raise capital at these levels.

• The Science Is Real, but Miles From Revenue

A Phase 1 trial for an autoimmune hair-loss drug is enrolling on schedule, with preliminary data expected in the first half of 2026 and full results in Q4.

Separately, a peer-reviewed journal published data in March showing the company's compound could improve how CAR-T cancer therapies are manufactured. Both are meaningful scientifically but years from generating product sales.

The bottom line: Nasdaq's extension buys time, not solvency. With negligible cash, going-concern warnings, and a stock price propped up by one-off deals, shareholders are betting that management can monetize promising but early-stage science before the clock — and the capital — run out.